BIIB - NASDAQ
Biogen Inc.
$195.96
+3.8%Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an etanercept biosimilar referencing ENBREL; ADUHELM for the treatment of Alzheimer's disease; IMRALDI, an adalimumab biosimilar referencing HUMIRA; and FLIXABI, an infliximab biosimilar referencing REMICADE. In addition, the company offers RITUXAN for treating non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; and OCREVUS for treating relapsing MS and primary progressive MS; and other anti-CD20 therapies. Further, it develops BIIB135, BIIB061, BIIB091, and BIIB107 for MS and neuroimmunology; Aducanumab, Lecanemab, BIIB076, and BIIB080 to treat Alzheimer's disease and dementia; BIIB067, BIIB078, BIIB105, BIIB100, and BIIB110 to treat neuromuscular disorders; BIIB124, BIIB094, BIIB118, BIIB101, and BIIB122 for treating Parkinson's disease and movement disorders; BIIB125 and BIIB104 for treating neuropsychiatry; Dapirolizumab pegol and BIIB059 to treat immunology related diseases; BIIB093 and BIIB131 to treat acute neurology; BIIB074 for neuropathic pain; and BYOOVIZ, BIIB800, and SB15 biosimilars, which are under various stages of development. The company has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis Co., Ltd.; Sangamo Therapeutics, Inc.; and Sage Therapeutics, Inc. Biogen Inc. was founded in 1978 and is headquartered in Cambridge, Massachusetts.
At a Glance
Live SnapshotBiogen Inc. Cash Conversion Engine
Cash Flow Quality Analysis
FCF Conversion Rate
Excellent cash generation. The company converts earnings to cash at or above 100%, indicating high-quality earnings.
CapEx Intensity
Asset-light business model. Low capital requirements leave more cash available for shareholders and growth investments.
FCF Growth Trend
Significant FCF decline raises concerns. Urgent review needed of operational performance and capital allocation.
Working Capital Impact
Significant working capital drain. Growth may be consuming cash through inventory buildup or receivables extension—monitor closely.
Cash Flow Quality Insight
Asset-light with strong cash conversion: Low capital requirements combined with efficient cash generation creates significant shareholder value through dividends, buybacks, or strategic investments.
Biogen Inc. Cash Flow Statement
BIIB • NASDAQ
| Biogen Inc. Cash Flow Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 | Dec 2007 | Dec 2006 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
OPERATING ACTIVITIES | ||||||||||||||||||||
1.3B | 1.6B | 1.2B | 3B | 1.7B | 4.1B | 5.9B | 4.5B | 2.7B | 3.7B | 3.6B | 2.9B | 1.9B | 1.4B | 1.3B | 898.6M | 977.1M | 783.2M | 638.2M | 217.5M | |
779.9M | 673.2M | 494.8M | 518.4M | 487.7M | 457.2M | 464.6M | 650.5M | 1.1B | 682.7M | 600.4M | 637.3M | 531.7M | 365.6M | 358.9M | 354.1M | 428M | 462.1M | 380.3M | 375.9M | |
361.6M | -158.1M | -305.8M | -168.6M | -426.8M | 149M | 67.1M | 108.3M | 91.7M | -175M | -145.6M | -308.2M | -245.1M | -116.9M | 153.6M | -81.4M | -137.4M | -139.5M | -81.6M | -106.3M | |
290.8M | 291.2M | 264.2M | 254.1M | 238.6M | 198.3M | 182.3M | 157.5M | 128M | 154.8M | 161.4M | 155.3M | 136.3M | 118.6M | 113M | 167.8M | 160.9M | 146.2M | 123.1M | 126.8M | |
537M | 592.2M | 581.2M | -1.3B | 1.8B | -448M | 276.7M | 397.2M | 344.8M | 91.2M | 82.2M | -50.3M | -27.6M | 28.8M | 20.2M | 282M | -2.2M | 136.2M | 38.5M | 324M | |
(0.0) | (355.1M) | (740.7M) | (932.9M) | (247.9M) | (906.7M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (372M) | (251.9M) | (397.9M) | |
-1.1B | -155.2M | -648.7M | -890.3M | -145.5M | -187.2M | 199.3M | 400.2M | 235.4M | 73M | -575.5M | -484.4M | 87.4M | 103.7M | -184.6M | 3.6M | -351.5M | 174.3M | -77.9M | -96.5M | |
2.2B | 2.9B | 1.5B | 1.4B | 3.6B | 4.2B | 7.1B | 6.2B | 4.6B | 4.5B | 3.7B | 2.9B | 2.3B | 1.9B | 1.7B | 1.6B | 1.1B | 1.6B | 1B | 841.3M | |
INVESTING ACTIVITIES | ||||||||||||||||||||
-153.8M | -359.8M | -311.4M | -243.2M | -294.9M | -551.8M | -669.5M | -886.1M | -2B | -727.7M | -643M | -287.8M | -3.5B | -261.2M | -252.2M | -173.1M | -165.6M | -276M | -284.1M | -198.3M | |
(0.0) | -1.1B | -6.9B | (595M) | (28.1M) | (0.0) | (179.3M) | (0.0) | (0.0) | (0.0) | -198.8M | (0.0) | -15M | -72.4M | -2.8M | -157.4M | (0.0) | -25M | -79.1M | -229.2M | |
-1.3B | (0.0) | -5.1B | -3.4B | -3.8B | -7.4B | -5.3B | -8.2B | -5.4B | -7.9B | -6.9B | -3.6B | -3.3B | -3.3B | -3.7B | -2B | -3.6B | -3.2B | -3B | -2B | |
79.7M | 551.5M | 8.3B | 4.7B | 3.5B | 7.4B | 6.5B | 9.2B | 5.6B | 7.4B | 4.1B | 2.7B | 5.2B | 2.8B | 2.3B | 2.7B | 3.4B | 3.1B | 3.3B | 1.8B | |
-38.7M | 83.9M | -11.3M | 24.4M | 12.9M | -26.9M | -273M | -1.5B | -1.2B | -1.2B | -909.9M | -391M | 7.4M | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
-1.4B | -799.2M | -4.1B | (1.6B) | -563.7M | -608.6M | (470.5M) | -2B | -3B | -2.5B | -4.6B | -1.5B | -1.6B | -950.3M | -1.7B | (345.3M) | -395M | -365.9M | -286.6M | -599.8M | |
FINANCING ACTIVITIES | ||||||||||||||||||||
-10M | -31.3M | -44.3M | -751.9M | -1.8B | -6.7B | -5.9B | -4.4B | -1.4B | -956.3M | -4.9B | -831.9M | -333.5M | -917.2M | -183.3M | -1.9B | -703.4M | -560.5M | -2.5B | -173.3M | |
-16.9M | -650M | 187.3M | -1B | -170M | 1.5B | 0.0 | -3.2M | -560.9M | -2.7M | 5.9B | -2.7M | -452.3M | -2.4M | -11.8M | 119.5M | -28.6M | -704.2M | 1.7B | -6.8M | |
(0.0) | (0.0) | (0.0) | -750M | -1.8B | -6.7B | -5.9B | -4.4B | -1.4B | -1B | -5B | -886.8M | -400.3M | -984.7M | -498M | -2.1B | -751.2M | -738.9M | -3B | -320.3M | |
-275M | -2.2M | -6M | -5.6M | -115.5M | -56.4M | 7.9M | -116.2M | -453.7M | -28.8M | 3.8M | 78.7M | 69.4M | 42.2M | -124.7M | -10.3M | 7.8M | 28M | 69.7M | 31.7M | |
-301.9M | -683.5M | 137M | -1.8B | -2.1B | -5.3B | -5.9B | -4.5B | -2.4B | -987.8M | 986.4M | -755.9M | -716.5M | -877.5M | -319.9M | -1.8B | -724.2M | -1.2B | -735.2M | -148.4M | |
CASH FLOW SUMMARY | ||||||||||||||||||||
101.9M | -67.7M | 35.1M | -55.7M | -59.8M | 69M | 400K | -18.6M | 39.4M | -31.3M | -45.8M | -40.9M | 8B | 4.1M | -2.6M | -7.4M | 3.8M | 776M | -558K | 124K | |
633.5M | 1.3B | -2.4B | 1.2B | 930.2M | -1.6B | 1.7B | -349.2M | -752.7M | 1B | 103.1M | 602.4M | 602.6M | 56.2M | -245.1M | 177.7M | -40.5M | -37.3M | -1.7M | 93.2M | |
2.4B | 1B | 3.4B | 2.3B | 1.3B | 2.9B | 1.2B | 1.6B | 2.3B | 1.3B | 1.2B | 602.6M | 570.7M | 514.5M | 759.6M | 581.9M | 622.4M | 659.7M | 661.4M | 568.2M | |
3B | 2.4B | 1B | 3.4B | 2.3B | 1.3B | 2.9B | 1.2B | 1.6B | 2.3B | 1.3B | 1.2B | 602.6M | 570.7M | 514.5M | 759.6M | 581.9M | 622.4M | 659.7M | 661.4M | |
2.1B | 2.5B | 1.2B | 1.1B | 3.4B | 3.8B | 6.6B | 5.3B | 3.7B | 3.9B | 3.1B | 2.6B | -1.2B | 1.6B | 1.5B | 1.5B | 909.3M | 1.3B | 736.5M | 643M |
SEC Filings
BIIB - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | April 29, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 29, 2026 | April 29, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 28, 2026 | June 09, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 06, 2026 | April 06, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 31, 2026 | March 31, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 11, 2026 | March 11, 2026 | 2026 | |
8-K 8-K 2026 N/A | February 11, 2026 | February 11, 2026 | 2026 | |
10-K 10-K 2025 FY FY | February 06, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | February 06, 2026 | February 06, 2026 | 2026 |
Related Guides
Continue your BIIB research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.